日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study

伊扎隆单抗布伦吉特康治疗局部晚期或转移性非小细胞肺癌（伴有除经典 EGFR 突变以外的可靶向基因组改变）：一项 Ib 期研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-01929
Zhou, Huaqiang; Zhao, Hongyun; Hou, Xue; Wang, Yongsheng; He, Zhiyong; Li, Yongsheng; Ma, Yuxiang; Zhao, Yuanyuan; Huang, Yan; Chen, Likun; Xiao, Sa; Zhu, Hai; Zhu, Yi; Fang, Wenfeng; Zhang, Li; Yang, Yunpeng
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2026
文献求助 收藏

A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.

针对晚期实体瘤的 B7H3 靶向抗体药物偶联物：一项 1/1b 期试验

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-03600-2
Ma Yuxiang, Yang Yunpeng, Huang Yan, Fang Wenfeng, Xue Jinhui, Meng Xiangjiao, Fan Yun, Fu Siqing, Wu Lin, Zheng Yulong, Liu Jian, Liu Zhihua, Zhuang Wu, Rosen Seth, Qu Song, Li Bihui, Li Mingjun, Zhao Yanqiu, Yang Shujun, Ji Yinghua, Sommerhalder David, Luo Suxia, Yang Kunyu, Li Jingao, Lv Dongqing, Zhang Peng, Zhao Yuanyuan, Hong Shaodong, Zhang Yang, Zhao Shen, Chin Steve, Zhang Xian, Lian Wei, Cai Jiaqiang, Xue Tongtong, Zhang Li, Zhao Hongyun
免疫/内分泌
H3
发表日期：2025
文献求助 收藏

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors

新型PARP1/2抑制剂CVL218治疗晚期实体瘤患者的I期临床试验

期刊:MedComm
影响因子:10.7
doi:10.1002/mco2.70272
Chen, Zihong; Chen, Gang; Ma, Yuxiang; Zhao, Hongyun; Zhan, Jianhua; Huang, Yan; Yang, Yunpeng; Zhao, Yuanyuan; Hong, Shaodong; Zhou, Ting; Fang, Wenfeng; Zhang, Li; Zhang, Yaxiong
PARP
PARP1
发表日期：2025
文献求助 收藏

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Izalontamab (SI-B001) 是一种新型 EGFRxHER3 双特异性抗体，用于治疗局部晚期或转移性上皮肿瘤患者：首次人体 I/Ib 期研究的结果。

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-0206
Xue Jinhui, Ma Yuxiang, Zhao Yuanyuan, Wang Yongsheng, Hong Wei, Huang Yan, Yang Yunpeng, Fang Wenfeng, Hong Shaodong, Zhang Yang, Liu Qianwen, Zhu Yi, Zhu Hai, Xiao Sa, Zhang Li, Zhao Hongyun
Human
肿瘤
EGF
NTA
EGFR
发表日期：2025
文献求助 收藏

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK (+) and ROS1 (+) non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial

口服APG-2449治疗晚期ALK(+)和ROS1(+)非小细胞肺癌患者的安全性、药代动力学、药效学和疗效：一项多中心、开放标签、单臂I期试验

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103556
Ma, Yuxiang; Song, Zhengbo; Chen, Jianhua; Zhao, Yanqiu; Fang, Wenfeng; Guo, Yubiao; Dong, Yugang; Yang, Yunpeng; Wu, Gang; Fang, Jian; Lin, Xiaoyan; Li, Jundong; Huang, Yan; Zhao, Yuanyuan; Hong, Shaodong; Xue, Jinhui; Zhang, Yang; Liu, Qianwen; Yang, Chen; Xu, Liang; Yang, Yun; Xiong, Dengkun; Yang, Dajun; Zhai, Yifan; Zhang, Li; Zhao, Hongyun
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2025
文献求助 收藏

Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial

福罗拉匹坦和帕洛诺司琼混合制剂（HR20013）联合地塞米松治疗计划接受高致吐性顺铂类化疗的实体瘤患者的药代动力学、安全性和疗效：一项 I 期试验

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04314-5
Zhao, Yuanyuan; Ma, Yuxiang; Yin, Tengrui; Qin, Zhiquan; Liu, Linlin; Kong, Guoqiang; Zhang, Ranran; Huang, Yuanyuan; Zhang, Li; Zhao, Hongyun
发表日期：2025
文献求助 收藏

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer

HS-10375，一种选择性EGFR C797S酪氨酸激酶抑制剂，用于治疗晚期非小细胞肺癌

期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/s12967-025-06613-0
Zhan, Jianhua; Xue, Jinhui; Wu, Lin; Zhang, Zhiye; Wang, Qiming; Ma, Yuxiang; Huang, Yan; Yang, Yunpeng; Zhao, Yuanyuan; Fang, Wenfeng; Zhang, Yang; Liu, Qianwen; Xu, Wen; Yang, Yan; Chen, Zhenming; Song, Baili; Sun, Danni; Sun, Xia; Gao, Peng; Zhao, Hongyun; Zhang, Li
肺癌
肿瘤
肿瘤免疫
信号转导
EGF
EGFR
细胞生物学
发表日期：2025
文献求助 收藏

Detection of early neurological deterioration using a quantitative electroencephalography system in patients with large vessel occlusion stroke after endovascular treatment

利用定量脑电图系统检测血管内治疗后大血管闭塞性卒中患者的早期神经功能恶化

期刊:Journal of Neurointerventional Surgery
影响因子:4.3
doi:10.1136/jnis-2024-022011
Yan, Yujia; An, Xingwei; Ma, Yuxiang; Jiang, Zeliang; Di, Yang; Li, Tingting; Wang, Honglin; Ren, Hecheng; Ma, Lin; Luo, Bin; Huang, Ying
神经科学
发表日期：2025
文献求助 收藏

Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I study

抗OX40抗体BAT6026治疗晚期实体瘤患者：一项多中心I期研究

期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2025.112270
Zhou, Huaqiang; Ma, Yuxiang; Li, Yongsheng; Tang, Long; Guo, Yubiao; Yuan, Gang; Fu, Ziyi; Yu, Jin-Chen; Zhang, Li; Zhao, Hongyun
发表日期：2025
文献求助 收藏

A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma

一种基于新型炎症标志物的晚期肺淋巴上皮瘤样癌预后模型

期刊:Journal of Inflammation Research
影响因子:4.1
doi:10.2147/JIR.S502286
Chen, Xueyuan; Liu, Tingting; Mo, Silang; Yang, Yuwen; Chen, Xiang; Hong, Shaodong; Zhou, Ting; Chen, Gang; Zhang, Yaxiong; Ma, Yuxiang; Ma, Yuanzheng; Zhang, Li; Zhao, Yuanyuan
肿瘤
炎症
肿瘤免疫
炎症/感染
Immunology/Inflammation
发表日期：2025
文献求助 收藏